[Recent advances in molecular pathogenesis of myeloproliferative neoplasms]

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Context:

• Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders.
• MPNs are characterized by activating mutations in JAK-STAT signaling pathway components, such as JAK2, MPL, and CALR.
• These mutations lead to excessive proliferation and differentiation of hematopoietic cells.

Purpose:

• To explore the role of epigenetic alterations in the pathogenesis and progression of MPNs.
• To identify potential novel therapeutic targets beyond JAK-STAT pathway inhibition.

Summary:

• Driver mutations in MPNs activate the JAK-STAT pathway, leading to hematopoietic cell abnormalities.
• Despite driver mutations like JAK2V617F causing proliferation, clonal advantage in repopulation is not guaranteed.
• Epigenetic modifiers, including histone modifications and DNA methylation changes, often coexist with driver mutations.
• These epigenetic alterations can upregulate oncogenes and are implicated in disease progression to myelofibrosis or acute leukemia.

Impact:

• Highlights the critical role of epigenetic dysregulation in MPN progression.
• Suggests that targeting molecules affected by epigenetic alterations could be a promising therapeutic strategy for MPNs.
• Expands understanding of MPN pathogenesis beyond driver mutations alone.